Drugs in Dev. Cardiology/Vascular Diseases
IND Enabling
Canada 
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Repair Biotechnologies
Deal Size : $107.0 million
Deal Type : Licensing Agreement
Repair Biotech, Genevant Partner on mRNA-LNP Therapy for Atherosclerosis
Details : Under the license agreement, Genevant will grant Repair a nonexclusive worldwide license to certain LNP technology to exploit CDP mRNA products for a specified field that includes atherosclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 26, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Repair Biotechnologies
Deal Size : $107.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
Details : The Company also confirmed in its own murine cortical neuron outgrowth preclinical study, that AP-188 (N,N-Dimethyltryptamine), in sub-psychedelic doses, increased the growth of cortical neurons by up to 40% compared to control.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 12, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study
Details : AP-188 (N,N-Dimethyltryptamine), or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Recurrent Pericarditis and inhibits activation of the inflammasome pathway.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A novel salt form of AP-188 (N, N-dimethyltryptamine), a hallucinogenic tryptamine drug, is a new and separate structure from the original compound, helps mitigate tissue damage and promote neurogenesis demonstrated in preclinical studies.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 24, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company received positive feedback from the UK MHRA for its planned Phase 1 DMT Stroke study for AP-188 (N,N-Dimethyltryptamine), a hallucinogenic tryptamine drug for the treatment of mental health disorders.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 19, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
Details : The data showed that an increase in growth of over 40% was observed in the group treated for 6 hours with 30 nM AP-188 or DMT, with statistical significance, when compared to control. The results from the 6-hour period were superior to other treatment ti...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
Details : The Phase 1 will investigate safety, dose, and the pharmacokinetics of DMT, while the Phase 2a part will additionally examine the use of DMT as an adjunctive treatment to Constraint-Induced Movement Therapy for the treatment of upper-limb dysfunction in ...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AP-188 (“N,N-Dimethyltryptamine or “DMT”), increased the growth of cortical neurons by 40% with statistical significance in one arm of the study, when compared to control. Algernon also reports that the increased growth was achieved with a sub hall...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 07, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
LQT Therapeutics Announces Closing of US$19M Series A Financing
Details : LQTT is advancing a series of in- licensed compounds discovered and developed by Sanofi S.A. (Paris, France) which inhibit Serum/Glucocorticoid Regulated Kinase 1 (SGK1).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 10, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
Reset All
